Maravai LifeSciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +44.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 9.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth F
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -40.5% | Better than 1% |
| Free cash flow CAGR (3Y) | -21.8% | Better than 17% |
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 18.3% | Better than 15% |
| Operating margin | -69.2% | Better than 8% |
| Net margin | -70.4% | Better than 8% |
| Return on equity | -48.6% | Better than 9% |
| Return on invested capital | -18.1% | Better than 14% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -19.2% | Better than 32% |
| 6-month return | 58.6% | Better than 96% |
| 12-month return (ex latest month) | 95.2% | Better than 95% |
| Distance below 52-week high | 25.9% | Better than 49% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.6x | Better than 90% |
| Debt to assets | 47.3% | Better than 18% |
| Interest coverage | -7.7x | Better than 14% |
| Free cash flow / net income | 235.6% | Better than 81% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 41.5% | Better than 60% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.19
- Open
- 7.06
- Day range
- 6.91 - 7.17
- Avg price
- 7.00
- Volume
- 1.79M
- Turnover
- 12.50M
- Turnover ratei
- 1.74%
- Volume ratioi
- 0.98
- Amplitudei
- 3.62%
- 52-week rangei
- 2.80 - 9.42
Valuation
- P/Ei
- -7.76
- P/E (TTM)i
- -15.86
- P/Bi
- 5.32
- EPSi
- -0.90
- Book value / shi
- 1.31
- Net profit
- -134.33M
- Net assets
- 195.82M
Share structure
- Market cap
- 1.04B
- Float capi
- 716.18M
- Shares out
- 149.25M
- Float sharesi
- 102.60M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-11-20
25.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-9.03M net over the window
Short interest
- Shares short
- 14.05M
- % of floati
- 9.43%
- Days to coveri
- 6.81
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Maravai LifeSciences (MRVI)?
Maravai LifeSciences last traded at 6.98. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Maravai LifeSciences's market cap?
About 1.04B.
What is the P/E ratio of Maravai LifeSciences?
The trailing twelve-month P/E is -15.86, below its own 5-year average of 3.54 — toward the bottom of its historical range (0.40% percentile). See the Valuation tab for the full history.
Does Maravai LifeSciences pay a dividend?
Maravai LifeSciences does not currently pay a regular dividend.
Is Maravai LifeSciences a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 9.88, which implies 41.5% upside from the current price. This is not investment advice.
What is Maravai LifeSciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Maravai LifeSciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Maravai LifeSciences discussion 0 comments